| 3.87 0.14 (3.75%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
iCAD, Inc. specializes in delivering advanced solutions for cancer management, encompassing sophisticated image analysis tools, streamlined workflow optimization, and targeted radiation therapy. While primarily operating in the United States, the company also maintains a significant international presence. Its operations are organized into two principal divisions: Cancer Detection and Cancer Therapy. In the Cancer Detection segment, iCAD provides a range of innovative technologies. This includes the PowerLook platform, which serves as a central host for artificial intelligence algorithms and facilitates seamless communication between imaging acquisition devices, storage systems, and review platforms. Key diagnostic offerings feature SecondLook, a machine learning-driven algorithm designed to examine 2D full-field digital mammography images for identifying and marking suspicious masses and calcifications. Additionally, the company offers automated solutions for consistent and standardized assessment of breast density. Its portfolio further extends to ProFound AI, a deep-learning algorithm adept at detecting malignant soft-tissue densities and calcifications within digital breast tomosynthesis, and ProFound AI Risk, a tool that provides breast cancer risk estimation derived from screening mammograms. Magnetic resonance imaging (MRI) applications are also available for detecting breast and prostate cancer, along with VeraLook, a solution supporting the identification of colonic polyps in conjunction with CT Colonography. The Cancer Therapy division features the Xoft Axxent electronic brachytherapy systems. These systems are employed in the treatment of early-stage breast, non-melanoma skin, and gynecological cancers. Their clientele is diverse, spanning university research centers, community hospitals, specialized cancer care clinics, veterinary facilities, and dermatology practices. iCAD distributes its products through multiple channels, utilizing its own direct sales organizations, as well as collaborating with original equipment manufacturer (OEM) partners, various distributors, technology platform partners, and resellers. The company also has a global footprint, exporting its advanced technologies to regions including Europe, Taiwan, Canada, China, and other international markets. Originally established in 1984 under the name Howtek, Inc., the company was rebranded as iCAD, Inc. in June 2002. Its corporate headquarters are located in Nashua, New Hampshire.
Mon, 31 Aug 2026
icad inc (ICAD) Key Financial Ratios – Valuation, Profitability & More - Value Research
Sun, 30 Aug 2026
icad inc (ICAD) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Fri, 18 Jul 2025
RadNet finalizes $103M acquisition of breast AI vendor iCAD amid legal opposition - Radiology Business
Thu, 17 Jul 2025
DeepHealth Completes Acquisition of iCAD - Imaging Technology News
Fri, 18 Apr 2025
Dentons represents iCAD, Inc. in its definitive merger agreement with RadNet, Inc. - Dentons
Thu, 17 Apr 2025
RadNet leaders discuss rationale behind blockbuster $103M iCAD AI acquisition - Radiology Business
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|